Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset

Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Günther, René, Balck, Alexander, Koch, Jan C., Nientiedt, Tobias, Sereda, Michael, Bähr, Mathias, Lingor, Paul, Tönges, Lars
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://ncbi.nlm.nih.gov/pubmed/28197100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados